Effectiveness and safety of pamidronate treatment in nonambulatory children with low bone mineral density
Open Access
- 29 February 2024
- journal article
- research article
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (1) , 46-53
Abstract
Purpose: Nonambulatory pediatric patients may have low bone mineral density (BMD) and increased risk of pathologic fractures. Though bisphosphonate therapy is the mainstream medical intervention in these children, clinical data regarding this treatment are limited. Therefore, this study aimed to evaluate the effectiveness and safety of bisphosphonate therapy in such children.Methods: We conducted a retrospective study of 21 nonambulatory children (Gross Motor Function Classification System level V) with BMD z-score ≤ -2.0 who were treated with intravenous pamidronate for at least 1 year. These patients received pamidronate every 4 months at a dose of 1.0 to 3.0 mg/kg for each cycle and had regular follow-ups for at least 1 year. The main outcome measures were changes in BMD, risk rate of fracture, biochemical data, and adverse events.Results: The average duration of pamidronate treatment was 2.0±0.9 years, and the mean cumulative dose of pamidronate according to body weight was 7.7±2.5 mg/kg/yr. After treatment, the mean lumbar spine bone mineral content, BMD, and height-for-age-z-score-adjusted BMD z-score (BMDhazZ) significantly improved. The relative risk of fracture after treatment was 0.21 (p=0.0032), suggesting that pamidronate treatment reduced fracture incidence significantly. The increase in the average dose per body weight in each cycle significantly increased the changes in BMDhazZ.Conclusion: Pamidronate treatment improved the bone health of nonambulatory children with low bone density without any significant adverse events. Independent of cumulative dosage and duration of treatment, the effectiveness of pamidronate increased significantly with an increase in the average dose per body weight in subsequent cycles.Keywords
This publication has 31 references indexed in Scilit:
- Peak bone mass from longitudinal data: Implications for the prevalence, pathophysiology, and diagnosis of osteoporosisJournal of Bone and Mineral Research, 2010
- Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsyDevelopmental Medicine & Child Neurology, 2010
- Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot studyDevelopmental Medicine & Child Neurology, 2006
- Bone densitometry in pediatric patients treated with pamidronatePediatric Radiology, 2005
- Bone disease in epilepsyCurrent Neurology and Neuroscience Reports, 2004
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaNew England Journal of Medicine, 1998
- Short-term Effects of Pamidronate on Biochemical Markers of Bone Metabolism in Osteoporosis—a Placebo-controlled Dose-finding StudyUpsala Journal of Medical Sciences, 1991
- Bone mineral loss and recovery after 17 weeks of bed restJournal of Bone and Mineral Research, 1990
- Pathologic Fractures in Severely Handicapped Children and Young AdultsJournal of Pediatric Orthopaedics, 1990